Johnson & Johnson's TREMFYA demonstrates strong efficacy in Crohn's disease trials, with 94% clinical remission and 61% endoscopic remission, bolstering the company's long-term growth outlook.
Johnson & Johnson's TREMFYA has demonstrated strong long-term efficacy in treating moderately to severely active Crohn's disease, with clinical remission rates reaching 94%. The data also highlights a significant 88% corticosteroid-free remission rate, which reinforces the drug's competitive positioning in the immunology market and supports long-term revenue growth expectations.
The study reported clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease.
88% of patients achieved 90-day corticosteroid-free clinical remission.
Johnson & Johnson reports positive long-term clinical data for TREMFYA, showing up to 94% clinical remission rates in patients with moderately to severely active Crohn's disease. The study also highlights that 88% of participants achieved corticosteroid-free remission at 90 days, strengthening the drug's competitive position in the immunology market.
The positive clinical data reinforces the commercial viability of TREMFYA as a key asset in Johnson & Johnson's immunology portfolio, likely supporting long-term revenue growth.